Drug Safety Monitoring Information
Analysis of administrative decisions of foreign regulatory authorities on the recall of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety profile, conducted by experts of the Scientific Centre for Expert Evaluation of Medicinal Products reveal...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2021-07-01
|
| Series: | Безопасность и риск фармакотерапии |
| Subjects: | |
| Online Access: | https://www.risksafety.ru/jour/article/view/218 |
| _version_ | 1826566371302965248 |
|---|---|
| author | E. V. Shubnikova E. O. Zhuravleva N. Yu. Velts P. M. Giulakhmedova A. A. Druzhinina |
| author_facet | E. V. Shubnikova E. O. Zhuravleva N. Yu. Velts P. M. Giulakhmedova A. A. Druzhinina |
| author_sort | E. V. Shubnikova |
| collection | DOAJ |
| description | Analysis of administrative decisions of foreign regulatory authorities on the recall of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety profile, conducted by experts of the Scientific Centre for Expert Evaluation of Medicinal Products revealed 19 administrative decisions. These decisions contained information on the following medicines registered in Russia: amikacin, tobramycin, gentamicin, neomycin, ciprofloxacin, delafloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, сeftriaxone, ceftaroline, rifapentine, tigecycline, bacitracin, ertapenem, daptomycin, erythromycin, fosfomycin, ampicillin+sulbactam, chloroquine, hydroxychloroquine. |
| first_indexed | 2024-03-08T22:26:58Z |
| format | Article |
| id | doaj.art-004bd778d7aa43728223c38b54e6c15e |
| institution | Directory Open Access Journal |
| issn | 2312-7821 2619-1164 |
| language | Russian |
| last_indexed | 2025-03-14T10:50:35Z |
| publishDate | 2021-07-01 |
| publisher | Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Безопасность и риск фармакотерапии |
| spelling | doaj.art-004bd778d7aa43728223c38b54e6c15e2025-03-02T10:50:04ZrusMinistry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Безопасность и риск фармакотерапии2312-78212619-11642021-07-019210310510.30895/2312-7821-2021-9-2-103-105186Drug Safety Monitoring InformationE. V. Shubnikova0E. O. Zhuravleva1N. Yu. Velts2P. M. Giulakhmedova3A. A. Druzhinina4Scientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsAnalysis of administrative decisions of foreign regulatory authorities on the recall of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety profile, conducted by experts of the Scientific Centre for Expert Evaluation of Medicinal Products revealed 19 administrative decisions. These decisions contained information on the following medicines registered in Russia: amikacin, tobramycin, gentamicin, neomycin, ciprofloxacin, delafloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, сeftriaxone, ceftaroline, rifapentine, tigecycline, bacitracin, ertapenem, daptomycin, erythromycin, fosfomycin, ampicillin+sulbactam, chloroquine, hydroxychloroquine.https://www.risksafety.ru/jour/article/view/218adverse reactionspostmarketing studiessecurity profiledrugsinstructions for medical usepharmacovigilance |
| spellingShingle | E. V. Shubnikova E. O. Zhuravleva N. Yu. Velts P. M. Giulakhmedova A. A. Druzhinina Drug Safety Monitoring Information Безопасность и риск фармакотерапии adverse reactions postmarketing studies security profile drugs instructions for medical use pharmacovigilance |
| title | Drug Safety Monitoring Information |
| title_full | Drug Safety Monitoring Information |
| title_fullStr | Drug Safety Monitoring Information |
| title_full_unstemmed | Drug Safety Monitoring Information |
| title_short | Drug Safety Monitoring Information |
| title_sort | drug safety monitoring information |
| topic | adverse reactions postmarketing studies security profile drugs instructions for medical use pharmacovigilance |
| url | https://www.risksafety.ru/jour/article/view/218 |
| work_keys_str_mv | AT evshubnikova drugsafetymonitoringinformation AT eozhuravleva drugsafetymonitoringinformation AT nyuvelts drugsafetymonitoringinformation AT pmgiulakhmedova drugsafetymonitoringinformation AT aadruzhinina drugsafetymonitoringinformation |